Form 8-K - Current report:
SEC Accession No. 0001437749-26-012303
Filing Date
2026-04-15
Accepted
2026-04-15 08:05:13
Documents
13
Period of Report
2026-04-15
Items
Item 7.01: Regulation FD Disclosure
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K rvph20260414_8k.htm   iXBRL 8-K 50211
2 EXHIBIT 99.1 ex_945819.htm EX-99.1 20233
  Complete submission text file 0001437749-26-012303.txt   213981

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA rvph-20260415.xsd EX-101.SCH 3580
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE rvph-20260415_def.xml EX-101.DEF 11422
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE rvph-20260415_lab.xml EX-101.LAB 15307
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rvph-20260415_pre.xml EX-101.PRE 11582
17 EXTRACTED XBRL INSTANCE DOCUMENT rvph20260414_8k_htm.xml XML 2856
Mailing Address 10080 N WOLFE ROAD SUITE SW3-200 CUPERTINO CA 95014
Business Address 10080 N WOLFE ROAD SUITE SW3-200 CUPERTINO CA 95014 4085018881
REVIVA PHARMACEUTICALS HOLDINGS, INC. (Filer) CIK: 0001742927 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38634 | Film No.: 26862571
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)